Billev Pharma East Ltd. proudly participated in the 2024 TOPRA Symposium, held from September 30 to October 2 in Rotterdam, the Netherlands. This prestigious event, co-organized with the Medicines Evaluation Board (MEB), the Netherlands’ national authority for medicines and health products, is widely regarded as Europe’s premier conference for regulatory affairs in healthcare.
The annual TOPRA Symposium, established in 2004, serves as a key platform for professionals in regulatory affairs, with dedicated programme streams for human medicines, medical devices and in-vitro diagnostics (IVDs), as well as veterinary medicines. The event draws a global audience of delegates, speakers, and exhibitors from industry, regulatory bodies, academia, and related sectors. Attendees gain insights into the latest trends and developments in the regulatory landscape while enjoying invaluable networking opportunities.
Billev Pharma East Ltd. was represented by Katja Pečjak Reven, M.Sc.Pharm., the company’s Director of BD, Sales and Marketing. She played a prominent role in the event, co-leading the fourth session of the Human Medicines Symposium (HM4) alongside Carlos Langezaal from Premier Consulting. The session, titled *Electronic Product Information (ePI): A Digital Passport for Medicinal Product Information*, explored the growing role of digital tools in improving the accessibility and accuracy of medicinal product information.
Through sessions like this, Billev Pharma East Ltd. continues to demonstrate its commitment to staying at the forefront of regulatory developments, contributing to shaping the future of healthcare regulatory affairs. In addition to attending talks, the company took full advantage of the event’s networking features, including the event app, which allowed delegates to exchange virtual business cards and establish connections with colleagues and exhibitors from across the industry.
The participation of Billev Pharma East Ltd. in the TOPRA 2024 Symposium underscores the company’s ongoing dedication to innovation and excellence in regulatory affairs.